27-Feb-2017 - Acticor Biotech has contracted QPS to manage a Phase I study of the company’s humanized Antibody Fragment, ACT017.
27-Feb-2017 - INC Research has expanded its Functional Service Provider (FSP) service offering to include investigator payment processing in response to increased transparency requirements.
23-Feb-2017 - QuintilesIMS has announced an offering of senior notes and a proposed debt refinancing as leadership looks to drive revenue growth, according to a Jefferies analyst.
23-Feb-2017 - Several organizations have penned an open letter to NIH urging it adhere to 21st Century Cures deadlines that if missed, will affect improvements to ClinicalTrials.gov – and ultimately, study start...
22-Feb-2017 - Pharmaceutical Product Development, LLC (PPD) is expanding its therapeutic expertise through a new collaboration with Frenova Renal Research.
22-Feb-2017 - Bioclinica has expanded its eHealth App xChange to make a greater range of technologies available to the increasing number of industry stakeholders – many with differing priorities.
22-Feb-2017 - iCardiac’s new eCOA platform, QPoint, can measure clinical outcome assessments from patients at home or during site visits and will soon integrate with emerging wearables.
21-Feb-2017 - The US Food & Drug Administration (FDA) has tasked Icon plc to validate three patient-reported outcomes (PRO) instruments in antibacterial drug trials.
20-Feb-2017 - The Research Institute for Chromatography (RIC) and Anacura have joined forces to create anaRIC biologics, an R&D and GMP analytical specialist CRO for biologics.
20-Feb-2017 - The EMA recently updated its Good Clinical Practice (GCP) Q&A to address several contractual arrangement “pitfalls” – specifically with electronic systems vendors.
20-Feb-2017 - The alliance expands the geographic reach of sponsors, giving customers real-time, EHR-based insight on the Taiwanese patient population.
17-Feb-2017 - Contract research organisation (CRO) ICON has taken a hit to its book-to-bill ratio after Pfizer dropped its anti-cholesterol candidate bococizumab in November.
16-Feb-2017 - High Point Clinical Trials Center (HPCTC) has partnered with Verified Clinical Trials to help prevent duplicate enrollment in clinical trials.
15-Feb-2017 - Quotient Clinical Ltd. has bought Charles River Laboratories’ contract manufacturing business, QS Pharma LLC.
15-Feb-2017 - Almac Discovery and the Royal College of Surgeons in Ireland (RCSI) and have announced a research collaboration aimed at understanding how to target therapy-resistant cancer tumors.
15-Feb-2017 - PRA Health Sciences and Takeda Pharmaceutical Company are expanding their partnership to Japan as Takeda accelerates the “transformation” of its R&D organization.
14-Feb-2017 - The Association of Clinical Research Professionals (ACRP) has published a new guidance addressing the standardization of competence required for clinical trial monitors.
14-Feb-2017 - Orgenesis’ Belgian subsidiary, Orgenesis SPRL, has received €12.3m ($12.8m) to further develop its Type 1 Diabetes program.
14-Feb-2017 - Beaufort, LLC has completed the multi-stage audit for the certification that it said separates it from other contract research organizations (CROs).
13-Feb-2017 - Researchers need to design more translationally relevant animal studies to improve the potential for success in human clinical trials, according a recent report.
13-Feb-2017 - Parexel has launched a mobile application for its ClinPhone® randomization and trial supply management (RTSM) service.
13-Feb-2017 - Pharm-Olam has secured an investment from Quad-C Management as the private equity firm eyes add-on acquisitions to complement organic growth.
10-Feb-2017 - BriaCell Therapeutics Corp. has submitted a chemistry, manufacturing and control (CMC) amendment to the US FDA before its planned stem-cell based vaccine trial for late stage breast cancer.
09-Feb-2017 - IntelGenx Corp. and Tetra Bio-Pharma Inc. have signed a binding term sheet for the development and commercialization of a drug product containing dronabinol.
09-Feb-2017 - Kitov Pharmaceuticals Holdings Ltd. is standing by the validity of its Phase III clinical trial data results as investigations begin.